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OBJECTIVES: Poor compliance with oral bisphosphonates
leads to increased risk of vertebral and hip fractures in
post-menopausal osteoporotic patients. Annual dose of
Zoledronic acid signiﬁcantly decreased risk of fractures as com-
pared to placebo. The objective of this study was to evaluate a
long-term cost-utility of the two strategies. METHODS: Markov
model was constructed and ﬁrst-order microsimulation was run
in order to compare long term health-economic impact of treat-
ments with Zoledronic acid and oral bisphosphonates in Czech
patients. Rather than clinical efﬁcacy, the model considered real-
life effectiveness of both treatments associated with medication
compliance. RESULTS: Compared to oral bisphosphonates the
treatment with Zoledronic acid showed systematically improved
effectiveness expressed as QALY gained throughout the life
expectancy. The incremental cost-effectiveness of the Zoledronic
acid is for 50 years of age below €25,708 per QALY gained and
decreases sharply for patients above 65 years, resulting in dis-
tinctly improved incremental cost-effectiveness ratio below
€6442 per QALY gained. CONCLUSIONS: From the age 65 on,
patients should be preferentially treated with Zoledronic acid
rather than oral bisphosphonates.
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COST-EFFECTIVENESS OF CELECOXIB COMPAREDTO
CONVENTIONAL NSAIDS AND NSAID+PPI COMBINATION
THERAPY IN RHEUMATOID ARTHRITIS
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OBJECTIVES: However, DMARDs are in the ﬁrst choice in the
treatment of rheumathoid arthritis (RA), several patients still
take NSAIDs, although, these drugs may cause serious gastro
intestinal (GI) side-effects under continuous use. COX2 inhibi-
tors supposed to have a better GI side-effect proﬁle. The aim of
our study was to evaluate the cost-effectiveness of the selective
COX2 inhibitor, celecoxib compared to conventional NSAIDs
and NSAID+PPI combination therapy. METHODS: A decision
tree model was developed, for one year, to simulate cohorts
within the three arms (celecoxib, NSAIDs, NSAID+PPI). Medical
costs, the costs of the side-effects (GI, cardio-vascular (CV)
events) and QALYs were calculated to gain ICER. One-way
deterministic sensitivity analyses were applied (tornado dia-
grams). Evaluations were made from a third party payer’s per-
spective. RESULTS: The results show that both NSAID+PPI
(ICER: €14,287/QALY) and celecoxib (ICER: €59,486/QALY)
offers extra health gain for extra money compared to NSAIDs.
NSAID+PPI seems to be the cost effective choice compared to
NSAID mono therapy. Celecoxib was dominated by NSAID+PPI
combination therapy. According to the sensitivity analyses
QALYs had the highest inﬂuence on ICER. CONCLUSIONS:
The selective COX2 inhibitor celecoxib seems to be an adequate
choice only for a limited group of patients with speciﬁc condi-
tions such as drug allergy or serious GI risk with no CV risk,
possibly with further PPI co-therapy.
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OBJECTIVES: To determine the most cost-util alternative in the
chronic treatment of Osteoarthritis METHODS: A study of
cost-utility was performed that used as source of information for
efﬁcacy a systematic review of the literature and as source of
costs a microcosting was done of each of the states of health
of the outcomes expected with chronic treatment. The quality of
life was validated by a panel of experts. As analytical tool, a
Markov model was used. The alternatives in competence were
non-steroid anti-inﬂammatories and inhibitors of COX-2, as
well as Piascledine. As state of health, hemorrhage of the upper
digestive tube, acute myocardial infarction, vascular cerebral
event and nephropathy were considered. The perspective of the
study was the public health services, in this case the Instituto
Mexicano del Seguro Social (IMSS); The analysis was performed
with a temporal horizon of 10 years, with a 3% discounting rate
for costs and effectiveness. The sensitivity analysis was one-way,
two-way and probabilistic RESULTS: Piascledine is the alterna-
tive that offers more years of life adjusted for quality of life
(17.03 QALYs), insofar as the AINE’s offer 14.17 QALY’s and
the Cox-2 13.96 QALY’s. The cost per QALY, is lower with
Piascledine ($333 USD) in comparison with AINE’s and Cox-2
$3397.00 USD and $2841.00 respectively. Piascledine is domi-
nant over AINE’s and Cox-2. Piascledine offers more net
economic beneﬁts and net health beneﬁts independently of
willingness to pay. CONCLUSIONS: Piascledine is a dominant
treatment in the chronic treatment of osteosrthritis versus AINEs
and COX-2.
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OBJECTIVES: The selective T cell co-stimulation modulator
abatacept was approved by EMEA in 2007 for the treatment of
moderate to severe active RA patients with an insufﬁcient
response or intolerance to disease-modifying anti-rheumatic
drugs (DMARDs), including at least one tumor necrosis factor-
alpha antagonist (anti-TNF). The objective of this study was to
assess the cost-effectiveness of abatacept in RA patients with an
inadequate response to anti-TNFs in the Hungarian setting.
METHODS: An individual state transition simulation cost-
utility model based on disease progression expressed in Health
Assessment Questionnaire (HAQ) disability index score change
was developed to enrol patients corresponding to the patients of
the ATTAIN clinical trial. This cost-utility analysis was con-
ducted using a societal perspective, including all costs (direct and
indirect) related to RA. We also present results from the perspec-
tive of Hungarian health insurance, where RA-related direct
costs are the most relevant. In this cost-utility assessment, abata-
cept was compared to methotrexate (MTX), the most prescribed
DMARDs. Current treatment patterns showing that patients
with an insufﬁcient response or intolerance to a ﬁrst anti-TNF
agent are switched to a subsequent anti-TNF agent, abatacept
was also compared to cycled anti-TNFs based on data from the
British Society of Rheumatology Biologics Registry. The model
was populated with Hungarian cost, utility and epidemiological
Abstracts A549
